Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

Author(s): M. Boyd, S. Ross, J. Owens, D. Hunter, J. Babich, M. R. Zalutsky, T. G. Hamilton, S. Bell, R. J. Mairs

Journal Name: Letters in Drug Design & Discovery

Volume 1 , Issue 1 , 2004

Become EABM
Become Reviewer


Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.

Keywords: noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [50 - 57]
Pages: 8
DOI: 10.2174/1570180043485743

Article Metrics

PDF: 28